Year: 2021
Type: article
Abstract: Cardiovascular and renal outcome trials categorically demonstrate the benefits of SGLT2 inhibitors (SGLT2i).Various pharmacotherapy algorithms recommend early use of SGLT2i, especially among those with existing cardiovascular disease, heart failure, or kidney disease.Despite a widening spectrum of patient eligibility, treatment gaps and clinical inertia still exist.
Source: The Singapore Family Physician
DOI: 10.33591/sfp.47.8.u1
Author: Goh Su-Yen
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4285355357